King's CorVu Gets Reluctant "No" From Advisory Committee
This article was originally published in The Pink Sheet Daily
Despite voting that King's CorVu is not equivalent to its study comparator, Cardio-Renal panel sees bright future for the stress agent.
You may also be interested in...
Cardio-renal advisory committee will review King's CorVue efficacy data from studies that departed from FDA's development guidance.
Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.
Of the leading candidates for FDA commissioner in the Obama administration, Margaret Hamburg seemed among those with the least relevant experience -- an illustrious career to be sure, but one that lacked a decision-making role involving medical products